Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950341465> ?p ?o ?g. }
- W2950341465 endingPage "343" @default.
- W2950341465 startingPage "336" @default.
- W2950341465 abstract "Dopamine receptor blocking agents (DRBAs), also known as antipsychotics, are medications widely used to treat a growing number of mental health diagnoses. However, their utility is limited by the potential to cause serious adverse movement reactions. Akathisia, dystonia, parkinsonism, and tardive dyskinesia (collectively known as extrapyramidal symptoms or EPSs) are associated with reduced social and occupational functioning, negative patient attitudes toward treatment, and nonadherence to pharmacotherapy. Neuroleptic malignant syndrome is a life-threatening reaction that can result from DRBA use and cause musculoskeletal dysfunction. The aim of this study is to profile patients who have developed DRBA-related movement adverse effects and identify risk factors significantly associated with each subtype of EPSs or other movement disorders (OMDs) such as neuroleptic malignant syndrome.A report of all potential DRBA-related EPSs or OMDs occurrences within a large community hospital network was generated using International Classification of Diseases, Ninth Revision (ICD-9) and 10th Revision (ICD-10) billing codes. Each patient encounter was manually reviewed to confirm that a documented case of DRBA-related EPSs or OMDs had indeed occurred and subsequently determine the likely causative agent(s).The resultant cohort of 148 patients experiencing unique DRBA-related EPS or OMD events was analyzed. The average patient was female, middle-aged, and overweight. The most common DRBAs precipitating EPSs or OMDs were haloperidol and quetiapine. In the population studied, age was significantly associated with the subtype of EPSs experienced such that those patients with akathisia and dystonia tended to be younger, whereas those with tardive dyskinesia tended to be older. Body mass index (BMI) category was also negatively correlated with the incidence of dystonia. In addition, it was observed that exposure to specific DRBAs, classes, and routes of administration significantly affected the risk of developing different subtypes of EPSs or OMDs in the study population.To our knowledge, this is the first study to describe an association between age and BMI with the risk of akathisia and dystonia, respectively, in patients taking DRBAs. Other trends observed with age and BMI in patients developing DRBA-related EPSs support previously reported findings. Expanding the knowledge base of individual characteristics associated with the risk of developing different subtypes of EPSs or OMDs can help providers and patients anticipate and attempt to mitigate these reactions, and may ultimately improve adherence to DRBA therapy." @default.
- W2950341465 created "2019-06-27" @default.
- W2950341465 creator A5045032869 @default.
- W2950341465 creator A5050843410 @default.
- W2950341465 creator A5053195432 @default.
- W2950341465 creator A5064666928 @default.
- W2950341465 creator A5083642082 @default.
- W2950341465 creator A5089922277 @default.
- W2950341465 date "2019-06-13" @default.
- W2950341465 modified "2023-09-29" @default.
- W2950341465 title "Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy" @default.
- W2950341465 cites W1469621249 @default.
- W2950341465 cites W1484674080 @default.
- W2950341465 cites W1513749687 @default.
- W2950341465 cites W1587602167 @default.
- W2950341465 cites W1762242056 @default.
- W2950341465 cites W1878816226 @default.
- W2950341465 cites W1883755617 @default.
- W2950341465 cites W1965973797 @default.
- W2950341465 cites W1975003823 @default.
- W2950341465 cites W1988891285 @default.
- W2950341465 cites W1997410926 @default.
- W2950341465 cites W1998824580 @default.
- W2950341465 cites W2003708274 @default.
- W2950341465 cites W2016117636 @default.
- W2950341465 cites W2018817967 @default.
- W2950341465 cites W2026767598 @default.
- W2950341465 cites W2027702746 @default.
- W2950341465 cites W2033470111 @default.
- W2950341465 cites W2033960179 @default.
- W2950341465 cites W2039549833 @default.
- W2950341465 cites W2047151451 @default.
- W2950341465 cites W2050045773 @default.
- W2950341465 cites W2050584393 @default.
- W2950341465 cites W2051026253 @default.
- W2950341465 cites W2057464084 @default.
- W2950341465 cites W2058819182 @default.
- W2950341465 cites W2059442013 @default.
- W2950341465 cites W2064640550 @default.
- W2950341465 cites W2070893229 @default.
- W2950341465 cites W2075050644 @default.
- W2950341465 cites W2085294427 @default.
- W2950341465 cites W2087190235 @default.
- W2950341465 cites W2088044851 @default.
- W2950341465 cites W2095755860 @default.
- W2950341465 cites W2096524981 @default.
- W2950341465 cites W2107274852 @default.
- W2950341465 cites W2110771821 @default.
- W2950341465 cites W2115547484 @default.
- W2950341465 cites W2122995141 @default.
- W2950341465 cites W2123028409 @default.
- W2950341465 cites W2124387474 @default.
- W2950341465 cites W2125205006 @default.
- W2950341465 cites W2129794283 @default.
- W2950341465 cites W2137601114 @default.
- W2950341465 cites W2137788868 @default.
- W2950341465 cites W2138218422 @default.
- W2950341465 cites W2148553600 @default.
- W2950341465 cites W2152061056 @default.
- W2950341465 cites W2159155203 @default.
- W2950341465 cites W2167404903 @default.
- W2950341465 cites W2168591853 @default.
- W2950341465 cites W2202043731 @default.
- W2950341465 cites W2328999320 @default.
- W2950341465 cites W2463675746 @default.
- W2950341465 cites W2754382591 @default.
- W2950341465 cites W2760367307 @default.
- W2950341465 cites W2807274421 @default.
- W2950341465 cites W2901243589 @default.
- W2950341465 cites W2908880843 @default.
- W2950341465 cites W4251953748 @default.
- W2950341465 cites W62870477 @default.
- W2950341465 cites W947803506 @default.
- W2950341465 doi "https://doi.org/10.1097/jcp.0000000000001061" @default.
- W2950341465 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6594730" @default.
- W2950341465 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31205194" @default.
- W2950341465 hasPublicationYear "2019" @default.
- W2950341465 type Work @default.
- W2950341465 sameAs 2950341465 @default.
- W2950341465 citedByCount "11" @default.
- W2950341465 countsByYear W29503414652020 @default.
- W2950341465 countsByYear W29503414652021 @default.
- W2950341465 countsByYear W29503414652022 @default.
- W2950341465 countsByYear W29503414652023 @default.
- W2950341465 crossrefType "journal-article" @default.
- W2950341465 hasAuthorship W2950341465A5045032869 @default.
- W2950341465 hasAuthorship W2950341465A5050843410 @default.
- W2950341465 hasAuthorship W2950341465A5053195432 @default.
- W2950341465 hasAuthorship W2950341465A5064666928 @default.
- W2950341465 hasAuthorship W2950341465A5083642082 @default.
- W2950341465 hasAuthorship W2950341465A5089922277 @default.
- W2950341465 hasBestOaLocation W29503414651 @default.
- W2950341465 hasConcept C118552586 @default.
- W2950341465 hasConcept C126322002 @default.
- W2950341465 hasConcept C15744967 @default.
- W2950341465 hasConcept C187212893 @default.
- W2950341465 hasConcept C197934379 @default.
- W2950341465 hasConcept C2776412080 @default.